Truist cuts Inspire Medical Systems stock price target on revenue outlook
Truist Securities reduced its price target for Inspire Medical Systems (NYSE:INSP) to $76 from $78, citing a revised 2028 revenue estimate of $937M. The stock trades at $67.21, considered undervalued. Q3 2026 results beat estimates, with revenue at $206.7M and EPS at $0.14. Wells Fargo raised its target to $69. Growth is expected to re-accelerate to low-single to mid-single digits in 2027-2028.
How this was made
The 30-second read
Why it matters
Earnings beat and target changes may drive short‑term price appreciation, but long‑term growth could be limited by capacity and competitive pressures.
Market read
The fresh earnings data and analyst actions provide a timely trading cue for INSP.
What to watch
Potential future reimbursement policy changes and the impact of CPT code adoption timing.
Background
Inspire Medical Systems (INSP) provides spinal cord stimulation devices; its recent earnings beat and analyst target revisions are new information.
Ticker impact
Truist lowered its price target to $76 and Wells Fargo raised its target to $69 after Inspire Medical Systems reported Q3 2026 earnings that beat estimates.
likely upward pressure as the market prices in the earnings beat and higher price targets
The beat was driven by better gross margin and lower operating expenses, and two major analysts moved targets higher, indicating fresh positive sentiment.
Market effects
Positive earnings may lift other medtech and device stocks tracking reimbursement trends.
U.S. small‑cap healthcare sector could see modest gains.
Limited to U.S. investors; no broader macro impact.
Counterpoint
The target cuts by Truist suggest lingering concerns over capacity constraints and GLP‑1 competition that could cap growth.
Key entities
- analystTruist Securities
Lowered price target to $76.
- analystWells Fargo
Raised price target to $69.



